Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2011-06-13
2011-11-08
Lundgren, Jeffrey S. (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S401000, C514S234800, C514S249000, C514S400000, C514S649000, C514S651000, C514S653000, C424S001250, C424S059000, C424S078050, C424S400000, C424S401000, C424S449000, C424S455000
Reexamination Certificate
active
08053427
ABSTRACT:
Improved topical gel compositions, such as those containing brimonidine, for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.
REFERENCES:
patent: 3278447 (1966-10-01), McNicholas
patent: 3560501 (1971-02-01), Walker
patent: 3594380 (1971-07-01), Sulkowski
patent: 3723432 (1973-03-01), Ott
patent: 3736297 (1973-05-01), Bracke
patent: 3740442 (1973-06-01), Ott
patent: 3890319 (1975-06-01), Danielewicz et al.
patent: 4029792 (1977-06-01), Danielewicz et al.
patent: 4164570 (1979-08-01), Clough et al.
patent: 4201211 (1980-05-01), Chandrasekaran et al.
patent: 4256763 (1981-03-01), McHugh
patent: 4285967 (1981-08-01), Gubernick et al.
patent: 5021416 (1991-06-01), Gluchowski
patent: 5077292 (1991-12-01), Gluchowski
patent: 5112822 (1992-05-01), Gluchowski
patent: 5130441 (1992-07-01), Gluchowski
patent: 5198442 (1993-03-01), Gluchowski
patent: 5204347 (1993-04-01), Gluchowski
patent: 5237072 (1993-08-01), Gluchowski
patent: 5300504 (1994-04-01), Gluchowski
patent: 5326763 (1994-07-01), Gluchowski et al.
patent: 5373010 (1994-12-01), Gluchowski et al.
patent: 5418234 (1995-05-01), Gluchowski et al.
patent: 5424078 (1995-06-01), Dziabo et al.
patent: 5442053 (1995-08-01), della Valle et al.
patent: 5552403 (1996-09-01), Burke et al.
patent: 5561132 (1996-10-01), Burke et al.
patent: 5587376 (1996-12-01), Burke et al.
patent: 5693646 (1997-12-01), Jones et al.
patent: 5696127 (1997-12-01), Jones et al.
patent: 5703077 (1997-12-01), Burke et al.
patent: 5714486 (1998-02-01), Burke et al.
patent: 5720962 (1998-02-01), Ivy et al.
patent: 5721237 (1998-02-01), Myers et al.
patent: 5736165 (1998-04-01), Ripley et al.
patent: 5753637 (1998-05-01), Fried
patent: 5756503 (1998-05-01), Burke et al.
patent: 5773440 (1998-06-01), Burke et al.
patent: 5916574 (1999-06-01), Fried et al.
patent: 6007846 (1999-12-01), Klar
patent: 6117871 (2000-09-01), Maurer et al.
patent: 6117877 (2000-09-01), Fogel
patent: 6194415 (2001-02-01), Wheeler et al.
patent: 6248741 (2001-06-01), Wheeler et al.
patent: 6284765 (2001-09-01), Caffrey
patent: 6294553 (2001-09-01), Gil et al.
patent: 6294563 (2001-09-01), Garst
patent: 6323204 (2001-11-01), Burke et al.
patent: 6387383 (2002-05-01), Dow et al.
patent: 6432934 (2002-08-01), Gilbard
patent: 6441047 (2002-08-01), DeSantis, Jr.
patent: 6444681 (2002-09-01), Flavahan et al.
patent: 6465464 (2002-10-01), Wheeler et al.
patent: 6468989 (2002-10-01), Chang et al.
patent: 6517847 (2003-02-01), Dow et al.
patent: 6534048 (2003-03-01), Borgman
patent: 7001615 (2006-02-01), Singh et al.
patent: 7014858 (2006-03-01), Ashley
patent: 7439241 (2008-10-01), DeJovin et al.
patent: 7709533 (2010-05-01), Wang et al.
patent: 7812049 (2010-10-01), Shanler et al.
patent: 7838563 (2010-11-01), DeJovin et al.
patent: 2002/0197300 (2002-12-01), Schultz et al.
patent: 2003/0017199 (2003-01-01), Woodward et al.
patent: 2003/0068343 (2003-04-01), Muizzuddin et al.
patent: 2003/0077301 (2003-04-01), Maibach et al.
patent: 2003/0087962 (2003-05-01), Demopulos et al.
patent: 2003/0229088 (2003-12-01), Gil et al.
patent: 2004/0092482 (2004-05-01), Gupta
patent: 2004/0156873 (2004-08-01), Gupta
patent: 2004/0220259 (2004-11-01), Yu et al.
patent: 2004/0242588 (2004-12-01), Dejovin et al.
patent: 2004/0254252 (2004-12-01), Engles et al.
patent: 2004/0266776 (2004-12-01), Gil et al.
patent: 2005/0020600 (2005-01-01), Scherer
patent: 2005/0059664 (2005-03-01), Gil et al.
patent: 2005/0059744 (2005-03-01), Donello et al.
patent: 2005/0196418 (2005-09-01), Yu et al.
patent: 2005/0276830 (2005-12-01), DeJovin et al.
patent: 2006/0057081 (2006-03-01), Boxrud
patent: 2006/0171974 (2006-08-01), DeJovin et al.
patent: 2006/0264515 (2006-11-01), Dejovin et al.
patent: 2007/0003622 (2007-01-01), Srinivasan et al.
patent: 2007/0082070 (2007-04-01), Stookey et al.
patent: 2007/0207222 (2007-09-01), Yu et al.
patent: 2007/0258935 (2007-11-01), McEntire et al.
patent: 2008/0181867 (2008-07-01), Lambert et al.
patent: 2008/0293728 (2008-11-01), McIntire et al.
patent: 2009/0060852 (2009-03-01), DeJovin et al.
patent: 2009/0061020 (2009-03-01), Theobald et al.
patent: 2009/0130027 (2009-05-01), Shanler et al.
patent: 2010/0021402 (2010-01-01), Dejovin et al.
patent: 2010/0028267 (2010-02-01), Horn
patent: 2010/0055153 (2010-03-01), Majmudar
patent: 2010/0130502 (2010-05-01), Dejovin et al.
patent: 2010/0227867 (2010-09-01), Dejovin et al.
patent: 2011/0118267 (2011-05-01), Dejovin
patent: 1090630 (2001-04-01), None
patent: 2090307 (2009-08-01), None
patent: 2213335 (2010-08-01), None
patent: 1381979 (1975-01-01), None
patent: 9100088 (1991-01-01), None
patent: 9613267 (1996-05-01), None
patent: 9625163 (1996-08-01), None
patent: 9836730 (1998-08-01), None
patent: 0076502 (2000-12-01), None
patent: 2004105703 (2004-12-01), None
patent: 2005002580 (2005-01-01), None
patent: 2005010025 (2005-02-01), None
patent: 2009082452 (2009-07-01), None
patent: 2009158646 (2009-12-01), None
patent: 2010136585 (2010-12-01), None
patent: WO2011053487 (2011-05-01), None
Arndt et al, “Manual of Dermatologic Therapeutics”, 7th Ed., pp. 176-177 (2007).
Berge et al, “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, vol. 66, No. 1, pp. 1-19 (1977).
Bockman et al, “Binding and Functional Characterization of Alpha-2 Andrenergic Receptor Subtypes on Pig Vascular Endothelium”, J. Pharmacol. Exp. Therapeutics, vol. 267, pp. 1126-1133 (1993).
Burke et al, “Preclinical Evaluation of Brimonidine”, Survey of Ophthalmology, vol. 41, pp. S9-S18 (1996).
Chein et al, “Comeal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342 and clonidine in rabbit eyes”, Current Eye Research, vol. 9, No. 11 pp. 1051-1059 (1990).
Chotani et al, “Silent asc-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries”, Am. J. Physiol. Heart Circ. Physiol., vol. 278, pp. H1075-H1083 (2000).
Cunliffe et al, Br. Med. J. 105 (1977).
Freedman et al, “Estrogen raises the sweating threshold in postmenopausal women with hot flashes”, Fertility and Sterility, vol. 77, No. 3, pp. 487-490 (2002).
Fuchs et al, “Heat, but not Mechanical Hyperalgesia, following Andrenergic Injections in Normal Human Skin”, Pain, vol. 90, Nos. 1-2, pp. 15-23 (2001).
Gennaro, “Remington: The Science and Practice of Pharmacy”, 19th Ed., pp. 866-885, 1517-1518, 1577-1597, 1672-1673 (1995).
Guarrera et al, “Flushing inRosacea: A Possible Mechanism”, Arch. Dermatol. Res., vol. 272, pp. 311-316 (1982).
Int'l Search Report issued on Mar. 29, 2011 in Int'l Application No. PCT/US2010/057184; Written Opinion.
Jeyara et al, “Cooling Evokes Redistribution of a2C-Andrenoceptors from Golgi to Plasma Membrance in Transfected Human Embryonic Kidney 293 Cells”, Molecular Pharmacology, vol. 60, No. 6, pp. 1195-1200 (2001).
Lindgren et al, “Effects of Some Antihypertensive Drugs on Cutaneous Blood Flow and Inflammatory Skin Responses Following Allergen Challenge in Guinea Pigs”, Pharmacology and Toxicology, vol. 60, pp. 364-367 (1987).
Material Safety Data Sheet, pp. 1-2 (1997).
McGhie, “Brimonidine: An alpha-2 adrenergic agonist for glaucoma”, Journal of the Pharmacy Society of Wisconsin, May/Jun. 2001, pp. 32-36.
Morrison et al, “Andrenergic Modulation of a Spinal Sympathetic Reflex in the Rat”, J. Pharmacol. Experim. Therap., vol. 273, No. 1, pp. 380-385 (1995).
Nakamura et al, “Peripheral analgesic action of clonidine: mediation by release of endogenous enkephlin-like substances”, European Journal of Pharmacology, vol. 146, pp. 223-228 (1988).
Nielsen et al, “Postjunctional a2-adrenoceptors mediate vasoconstriction in human subcutaneous resistance vessels”, Br. J. Pharmacol., vol. 97, pp. 829-834 (1989).
Ramey et al, “Rhinitis medicamentosa”, J Investig Allergol Clin Inim
Buge Jean-Christophe
Meunier Cyril
Nadau-Fourcade Karine
Galderma R&D SNC
Lee William
Lundgren Jeffrey S.
Panitch Schwarze Belisario & Nadel LLP
LandOfFree
Brimonidine gel composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Brimonidine gel composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Brimonidine gel composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4311105